ALK-Abelló Logo

ALK-Abelló

Develops allergy immunotherapy (AIT) and emergency treatments for severe allergies.

ALK | CO

Overview

Corporate Details

ISIN(s):
DK0061802139
LEI:
529900SGCREUZCZ7P020
Country:
Denmark
Address:
Bøge Alle 6-8, 2970 Hørsholm
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

ALK-Abelló is a global pharmaceutical company specializing in the research, development, and manufacturing of allergy immunotherapy (AIT) products. A pioneer in the field for over a century, the company focuses on creating treatments that address the underlying cause of allergies, rather than merely managing symptoms. Its portfolio encompasses a range of evidence-based AIT products, including tablets, drops, and injections, as well as emergency treatments for severe allergic reactions like anaphylaxis. ALK's primary therapeutic areas are respiratory allergies, food allergies, and anaphylaxis. The company is committed to scientific innovation and expanding access to its solutions, such as needle-free adrenaline treatments, to improve the lives of people with allergies worldwide.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-12 17:17
Regulatory News Service
Danish 102.5 KB
2025-11-12 17:17
Earnings Release
Danish 3.3 KB
2025-11-12 17:17
Regulatory News Service
English 104.1 KB
2025-11-12 17:17
Earnings Release
English 2.8 KB
2025-09-17 09:44
M&A Activity
Danish 174.5 KB
2025-09-17 09:44
M&A Activity
Danish 10.0 KB
2025-09-17 09:44
M&A Activity
English 8.9 KB
2025-09-17 09:44
M&A Activity
English 274.6 KB
2025-08-21 07:30
Earnings Release
English 11.5 KB
2025-08-21 07:30
Interim Report
English 505.8 KB
2025-08-21 07:30
Interim Report
English 505.8 KB
2025-08-21 07:30
Earnings Release
English 12.0 KB
2025-08-12 14:45
Earnings Release
Danish 103.0 KB
2025-08-12 14:45
Earnings Release
Danish 3.7 KB
2025-08-12 14:45
Earnings Release
English 108.6 KB

Automate Your Workflow. Get a real-time feed of all ALK-Abelló filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ALK-Abelló

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for ALK-Abelló via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Cabaletta Bio, Inc. Logo
Develops engineered T cell therapies for a curative reset in autoimmune diseases.
United States of America
CABA
Cadrenal Therapeutics, Inc. Logo
Developing novel anticoagulant therapies for high-risk cardiovascular patients.
United States of America
CVKD
CalciMedica, Inc. Logo
Develops CRAC channel inhibitors for critical illnesses like acute pancreatitis & AKI.
United States of America
CALC
Calidi Biotherapeutics, Inc. Logo
Develops immunotherapies using stem cells to deliver oncolytic viruses against solid tumors.
United States of America
CLDI
Calliditas Therapeutics Logo
Develops and commercializes novel treatments for rare renal and hepatic diseases like IgA nephropathy.
Sweden
CALTX
CALTH. Inc Logo
Develops AI-powered rapid diagnostic solutions for point-of-care and self-testing.
South Korea
402420
CAMBRIDGE NUTRITIONAL SCIENCES PLC Logo
Develops and manufactures diagnostic tests for food sensitivity and gut health.
United Kingdom
CNSL
Camp4 Therapeutics Corp Logo
Developing RNA-based therapies to upregulate genes for rare metabolic and CNS disorders.
United States of America
CAMP
Camurus Logo
Develops long-acting medicines for severe chronic diseases using advanced drug delivery.
Sweden
CAMX
Clinical-stage biopharma developing novel cancer drugs aiming for fewer side effects.
Japan
4575

Talk to a Data Expert

Have a question? We'll get back to you promptly.